-
公开(公告)号：US11006994B2
公开(公告)日：2021-05-18
申请号：US15527499
申请日：2015-11-19
Inventor： Yakov Krasik , Joshua Felsteiner , Yakov Slutsker , Ziv Gil , Jacob Cohen , Yoav Binenbaum
Abstract: A system for generating cold plasma is presented, suitable for use in in-vivo treatment of biological tissue. The system comprising: a control unit connectable to an elongated member at a first proximal end of the elongated member. The elongated member comprises a plasma generating unit at a second distal end thereof and gas and electricity transmission channels extending from said first proximal end towards said plasma generating unit. The control unit comprises a gas supply unit configured to provide predetermined flow rate of selected gas composition through said gas transmission channel and a power supply unit configured to generate selected sequence of high-frequency electrical pulses, typically in mega Hertz range, directed through said electricity transmission channel, thereby providing power and gas of said selected composition to the plasma generating unit for generating cold plasma.
-
公开(公告)号：US10927414B2
公开(公告)日：2021-02-23
申请号：US16449585
申请日：2019-06-24
Applicant: Technion Research & Development Foundation Limited , Ramot at Tel-Aviv University Ltd. , Walter Gabriel Wasser , Rambam Med-Tech Ltd.
Inventor： Karl Skorecki , Shay Tzur , Saharon Rosset , Walter Gabriel Wasser , Doron M. Behar , Revital Shemer
IPC: C12Q1/6883 , C12Q1/70 , G01N33/68
Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequilibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.
-
13.发明申请公开(公告)号：US20190309300A1
公开(公告)日：2019-10-10
申请号：US16316677
申请日：2017-07-13
Inventor： Izhak KEHAT , Alon ABEND , Omer SHKEDI , Lilac CASPI
IPC: C12N15/113 , A61P9/10 , A61K31/506 , A61K31/5377 , A61K31/713
Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.
-
公开(公告)号：US20240199703A1
公开(公告)日：2024-06-20
申请号：US18287276
申请日：2022-04-18
Applicant: RAMBAM MED-TECH LTD.
Inventor： Yona NADIR
CPC classification number: C07K14/001 , A61L15/32 , A61P7/04 , C07K4/00 , A61K38/00
Abstract: There is provided procoagulant peptides, and use of same, such as in treatment of hemostasis-related diseases or disorders, and/or wound healing.
-
公开(公告)号：US20240117438A1
公开(公告)日：2024-04-11
申请号：US18538027
申请日：2023-12-13
Inventor： Shai SHEN-ORR , Yehuda CHOWERS , Shiran GERASSY-VAINBERG , Alexandra BLATT , Elina STAROVETSKY , Renaud Gilles GAUJOUX , Naama MAIMON
IPC: C12Q1/6883 , C07K16/24 , G01N33/564
CPC classification number: C12Q1/6883 , C07K16/241 , G01N33/564 , C12Q2600/106 , C12Q2600/158 , G01N2800/52
Abstract: The present invention is directed to a kit and a method for determining the suitability of a subject to a treatment using a tumor necrosis factor alpha (TNFα). Further provided is a method for treating the subject determined to be suitable for a treatment using a TNFα inhibitor.
-
Patent Agency Ranking
16.发明公开公开(公告)号：US20240018592A1
公开(公告)日：2024-01-18
申请号：US18033582
申请日：2021-10-26
Inventor： Shai S. SHEN-ORR , Yehuda CHOWERS , Ayelet ALPERT , Shiran GERASSY-VAINBERG , Erik FELDMAN
IPC: C12Q1/6883 , C12Q1/6837
CPC classification number: C12Q1/6883 , C12Q1/6837 , C12Q2600/158 , C12Q2600/106
Abstract: A method of analyzing the therapeutic efficacy of a therapeutic agent for treating an immune-related disorder is disclosed. The method comprises contacting blood cells of the subject with the agent, measuring the expression of at least 20 genes in the blood cells of the subject; obtaining an immune age value based on the expression of the at least 20 genes, and comparing the immune age value with an immune age value of the subject calculated on the basis of expression of the at least 20 genes in blood cells of the subject, in the absence of the agent.
-
公开(公告)号：US11740225B2
公开(公告)日：2023-08-29
申请号：US15972671
申请日：2018-05-07
Inventor： Iyad Khamaysi , Eyal Zussman
IPC: G01N33/487 , G01N33/574 , A61B10/04 , A61B17/34 , G01N11/14
CPC classification number: G01N33/487 , A61B10/04 , A61B17/3403 , G01N33/57438 , A61B2010/045 , A61B2017/3413 , G01N11/14 , G01N2203/0089 , G01N2333/705 , G01N2333/928
Abstract: The present invention provides methods for determining malignancy in a cyst by measuring viscosity of cyst fluid while under stain. The invention further provides devices, and computer program products for determining same.
-
公开(公告)号：US20210262032A1
公开(公告)日：2021-08-26
申请号：US17260428
申请日：2019-07-15
Inventor： Yehuda CHOWERS , Shai SHEN-ORR , Shiran VAINBERG , Elina STAROSVETSKY , Sigal PRESSMAN , Alexandra BLATT
IPC: C12Q1/6883 , C07K16/28 , A61K31/661 , G01N33/92
Abstract: Methods of determining suitability of a subject to treatment with an agent that reduces localized inflammation and for converting an unsuitable subject to a suitable one are provided. Kits comprising molecules for doing same are also provided.
-
公开(公告)号：US11060092B2
公开(公告)日：2021-07-13
申请号：US16316677
申请日：2017-07-13
Inventor： Izhak Kehat , Alon Abend , Omer Shkedi , Lilac Caspi
IPC: A61K48/00 , C07H21/04 , C12N15/113 , A61P9/10 , A61K31/506 , A61K31/5377 , A61K31/713 , A61K45/06 , A61K38/15 , A61K38/12
Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.
-
公开(公告)号：US20170202900A1
公开(公告)日：2017-07-20
申请号：US15125340
申请日：2015-03-09
Applicant: HEALTH CORPORATION - RAMBAM MED-TECH LTD.
Inventor： Yona Nadir , Benjamin Brenner
IPC: A61K38/00
CPC classification number: A61K38/005 , A61K38/57
Abstract: The present invention is directed to peptides derived from certain domains of tissue factor pathway inhibitor (TFPI) for use in the treatment of solid tumors and diseases or disorders associated with abnormal clotting.
-
-
-
-
-
-
-
-
-
Search Results
39
records
(took 0.022 seconds)
